Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential


Relmada Therapeutics Inc RLMD has announced topline results of the human abuse potential (HAP) study with REL-1017 for major depressive disorder or MDD.

  • REL-1017 is a novel NMDA receptor (NMDAR) channel blocker and the Company's lead candidate.
  • The results showed that all three doses of REL-1017 (25 mg, 75 mg, and 150 mg) tested in recreational drug users demonstrated a substantial (30+ points) and statistically significant difference vs. intravenous ketamine 0.5 mg/kg over 40 minutes and were statistically equivalent to placebo.
  • Related: Relmada Stock Falls After Equity Raise Of $150M To Fund Depression Candidate.
  • Sergio Traversa, CEO of Relmada Therapeutics, said the results demonstrated that REL-1017 strongly differentiates from ketamine and is comparable to placebo for the maximum effect for Drug Liking 'at this moment." 
  • The data are consistent with previously generated results of the REL-1017 vs. oxycodone HAP study, which showed no meaningful abuse potential on the opioid domain.
  • Price Action: RLMD shares are up 7.06% at $19.56 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!